Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emerging concerns when evidence-based medicine is translated into real life: the case of neoadjuvant chemotherapy in ovarian cancer.

Literature DB >> 23054938

Emerging concerns when evidence-based medicine is translated into real life: the case of neoadjuvant chemotherapy in ovarian cancer.

Antonio González-Martín¹, Luis Chiva.

Abstract

Entities: Disease

Mesh：

Substances：
Antineoplastic Agents

Year: 2013 PMID： 23054938 DOI： 10.1007/s11912-012-0278-0

Source DB: PubMed Journal: Curr Oncol Rep ISSN： 1523-3790 Impact factor: 5.075

× No keyword cloud information.

13 in total

1. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.

Authors: Robert E Bristow; Dennis S Chi
Journal: Gynecol Oncol Date: 2006-07-27 Impact factor: 5.482

Review 2. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.

Authors: Gavin C E Stuart; Henry Kitchener; Monica Bacon; Andreas duBois; Michael Friedlander; Jonathan Ledermann; Christian Marth; Tate Thigpen; Edward Trimble
Journal: Int J Gynecol Cancer Date: 2011-05 Impact factor: 3.437

3. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Authors: Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed
Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245

4. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).

Authors: Dennis S Chi; Fernanda Musa; Fanny Dao; Oliver Zivanovic; Yukio Sonoda; Mario M Leitao; Douglas A Levine; Ginger J Gardner; Nadeem R Abu-Rustum; Richard R Barakat
Journal: Gynecol Oncol Date: 2011-09-13 Impact factor: 5.482

5. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?

Authors: S M Eisenkop; N M Spirtos
Journal: Gynecol Oncol Date: 2001-09 Impact factor: 5.482

6. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

Authors: Robert E Bristow; Rafael S Tomacruz; Deborah K Armstrong; Edward L Trimble; F J Montz
Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544

7. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors: Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal: Cancer Date: 2009-03-15 Impact factor: 6.860

8. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

Authors: Dennis S Chi; Eric L Eisenhauer; Oliver Zivanovic; Yukio Sonoda; Nadeem R Abu-Rustum; Douglas A Levine; Matthew W Guile; Robert E Bristow; Carol Aghajanian; Richard R Barakat
Journal: Gynecol Oncol Date: 2009-04-23 Impact factor: 5.482